[EN] OXABOROLE ESTERS AND USES THEREOF<br/>[FR] ESTERS D'OXABOROLE ET LEURS UTILISATIONS
申请人:ANACOR PHARMACEUTICALS INC
公开号:WO2017195069A1
公开(公告)日:2017-11-16
The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
Compositions for enhancing memory and methods therefor
申请人:Baudry Michel
公开号:US20060063707A1
公开(公告)日:2006-03-23
Compositions for enhancing memory of a subject comprising a combination of a positive modulator of an AMPA receptor and a positive modulator of an NMDA receptor are provided, wherein each modulator of the combination is present at a subtherapeutic dose for effecting memory enhancement. Methods for using such compositions in the treatment of cognitive impairment associated with aging, age-related diseases, and CNS disorders, for example, are provided. New fusion molecules are also provided that combine the positive modulator functionalities into one molecule.
Catalytic transformation of serine-O-carbonate to S-aryl cysteine derivatives was successfully achieved in the presence of Li+ by the use of a pyridoxalmodelcompoundhaving an ionophore function, which is the first example mimicking cystathionine β-synthase, artificially.
N-transfer reagent and method for preparing the same and its application
申请人:NATIONAL CHENG KUNG UNIVERSITY
公开号:US11040939B1
公开(公告)日:2021-06-22
Provided are a novel N-transfer reagent and a method for preparing the same and its application. The N-transfer reagent is represented by the following Formula (I):
The various novel N-transfer reagents of the present invention can be quickly prepared by employing different nitrobenzene precursors. The N-transfer reagents can directly convert a variety of amino compounds into diazo compounds under mild conditions. Particularly, the N-transfer reagents can facilitate the synthesis of the diazo compounds. The application of synthesizing diazo compounds of the present invention can greatly decrease the difficulty in operation, increase the safety during experiments, reduce the cost of production and the environmental pollution, and enhance the industrial value of diazo compounds.
[EN] VITRONECTIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR DE LA VITRONECTINE
申请人:SMITHKLINE BEECHAM CORPORATION
公开号:WO1999045927A1
公开(公告)日:1999-09-16
(EN) Pharmaceutically active compounds which inhibit the vitronectin receptor and are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporosis.(FR) La présente invention concerne des composés pharmaceutiquement actifs inhibiteurs du récepteur de la vitronectine. Ces composés conviennent pour le traitement de l'inflammation, du cancer, et de troubles cardio-vasculaires tels que l'athérosclérose et la resténose. Ces composés conviennent également pour le traitement de maladies où intervient une résorption osseuse, et notamment l'ostéoporose.